Gland Pharma Ltd. saw its shares rally by 10% in Tuesday's trading session following the announcement of its first-quarter results. The pharmaceutical manufacturer, specializing in small volume parental solutions, significantly outperformed market expectations for the June quarter (Q1FY27), beating revenue, EBITDA, and PAT estimates by 5-9%.
Q1 Performance Exceeds Expectations
The strong financial performance was primarily fueled by robust growth in the United States and European markets. In contrast, other core markets and the Rest of World (ROW) segment experienced subdued performance during the quarter. Looking ahead, Gland Pharma has provided optimistic guidance, projecting a 15-16% year-over-year revenue growth in constant currency terms for FY27. The company further aspires to achieve a 20% Compound Annual Growth Rate (CAGR) from FY28 onward over the subsequent four years. This growth is expected to be driven by the scaling up of recently secured contracts, increased off-take of its base products, and improved capacity utilization across its facilities.
Analyst Outlook and Target Prices
Following the impressive Q1 results, the stock reached a high of Rs 2,929.65 on the BSE. However, analyst opinions on Gland Pharma's future share price vary widely:
- Jefferies holds the highest target price on the Street at Rs 3,350.
- Nomura and Investec also set high targets, both at Rs 3,330.
- Motilal Oswal Financial Services (MOFSL) raised its estimates and set a target of Rs 3,080, citing a healthy pace of differentiated product launches and currency tailwinds.
- Equirus Securities maintained a 'LONG' rating with a September 2027 target of Rs 2,985, anticipating a 20% EBITDA CAGR over FY26–29E.
- Elara Securities, while acknowledging sustained growth momentum, downgraded the stock to 'Accumulate' from 'Buy' with a target of Rs 2,956, noting that upside might be capped after a nearly 40% run-up in the stock price over the past three months.
- ICICI Securities has a target of Rs 2,825, and Nirmal Bang at Rs 2,885.
- On the lower end, IIFL set a target of Rs 2,435.
- Goldman Sachs issued a 'Sell' rating with a target of Rs 2,125.
- The lowest target on the Street comes from Ambit Capital, suggesting Rs 1,940.
The Bloomberg consensus target price for Gland Pharma currently stands at Rs 2,672.53, which implies a potential downside of 6.4% from current levels, highlighting the mixed sentiment among market analysts despite the strong quarterly performance and optimistic company guidance.